Evidence map›Paper›PMID 22247754›Full record

ArticlePloS one2012

Genome-wide association of implantable cardioverter-defibrillator activation with life-threatening arrhythmias.

Sarah S Murray, Erin N Smith, Nikki Villarasa, Tara Nahey, Jeff Lande, Harold Goldberg, Marian Shaw, Lawrence Rosenthal, Brian Ramza, Jamshid Alaeddini and 6 more

Registry-linked trialOpen access · goldAbstract readComparative Study
In one paragraph

Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00664807 (Medtronic Genetic Arrhythmia Markers for Early Detection), which is not on this map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00664807 completednot on this map

Medtronic Genetic Arrhythmia Markers for Early Detection

TypeobservationalSponsorMedtronic Corporate Technologies and New VenturesRan2008 to 2009Enrolled1,023ConditionsDeath, Sudden, Cardiac, Ventricular Fibrillation, Tachycardia, Atrial Fibrillation
3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Systems biology and cardiac arrhythmias.Lancet (London, England) · 2012
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 7 institutions in 1 country.

Sarah S MurrayScripps Genomic Medicine, Scripps Translational Science Institute, La Jolla, California, United States of America.
Erin N Smith
Nikki Villarasa
Tara Nahey
Jeff Lande
Harold Goldberg
Marian Shaw
Lawrence Rosenthal
Brian Ramza
Jamshid Alaeddini
Xinqiang Han
Samir Damani
Orhan Soykan
Robert C Kowal
Eric J Topol
GAME Investigators
Medtronic (United States) · USScripps Research Institute · USBaylor University Medical Center · USRady Children's Hospital-San Diego · USRichmond Behavioral Associates · USSaint Luke's Health System · USSequenom (United States) · US

Funding

SCRIPPS TRANSLATIONAL SCIENCE INSTITUTE (UL1)UL1RR025774 · NCRR · SCRIPPS RESEARCH INSTITUTE, THE · PI TOPOL, ERIC JEFFREY · 2008 to 2011
$16.3M
NCRR NIH HHS UL1 RR025774NCRR NIH HHS UL1RR025774
6 · The paper itself

Abstract

objectivesTo identify genetic factors that would be predictive of individuals who require an implantable cardioverter-defibrillator (ICD), we conducted a genome-wide association study among individuals with an ICD who experienced a life-threatening arrhythmia (LTA; cases) vs. those who did not over at least a 3-year period (controls).

backgroundMost individuals that receive implantable cardioverter-defibrillators never experience a life-threatening arrhythmia. Genetic factors may help identify who is most at risk.

methodsPatients with an ICD and extended follow-up were recruited from 34 clinical sites with the goal of oversampling those who had experienced LTA, with a cumulative 607 cases and 297 controls included in the analysis. A total of 1,006 Caucasian patients were enrolled during a time period of 13 months. Arrhythmia status of 904 patients could be confirmed and their genomic data were included in the analysis. In this cohort, there were 704 males, 200 females, and the average age was 73.3 years. We genotyped DNA samples using the Illumina Human660 W Genotyping BeadChip and tested for association between genotype at common variants and the phenotype of having an LTA. RESULTS AND

conclusionsWe did not find any associations reaching genome-wide significance, with the strongest association at chromosome 13, rs11856574 at P = 5×10⁻⁶. Loci previously implicated in phenotypes such as QT interval (measure of the time between the start of the Q wave and the end of the T wave as measured by electrocardiogram) were not found to be significantly associated with having an LTA. Although powered to detect such associations, we did not find common genetic variants of large effect associated with having a LTA in those of European descent. This indicates that common gene variants cannot be used at this time to guide ICD risk-stratification.

trial registrationClinicalTrials.gov NCT00664807.

Indexed as

Defibrillators, ImplantableGenome-Wide Association StudyAgedArrhythmias, CardiacCase-Control StudiesCohort StudiesDNA Copy Number VariationsFemaleFollow-Up StudiesGenetic VariationGenotypeHumansMaleSurvival Rate

Identifiers

PMID22247754
PMCPMC3256134
OpenAlexW2030440265

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.